Recommended Standards for the Performance of Transesophageal Echocardiographic Screening for Structural Heart Intervention: From the American Society of Echocardiography

TY - JOUR

T1 - Recommended Standards for the Performance of Transesophageal Echocardiographic Screening for Structural Heart Intervention

T2 - From the American Society of Echocardiography

AU - Hahn, Rebecca T.

AU - Saric, Muhamed

AU - Faletra, Francesco Fulvio

AU - Garg, Ruchira

AU - Gillam, Linda D.

AU - Horton, Kenneth

AU - Khalique, Omar K.

AU - Little, Stephen H.

AU - Mackensen, G. Burkhard

AU - Oh, Jae

AU - Quader, Nishath

AU - Safi, Lucy

AU - Scalia, Gregory M.

AU - Lang, Roberto M.

N1 - Funding Information: The following authors reported relationships with one or more commercial interests: Rebecca T. Hahn, MD, FASE, has received speaker fees from Abbot Vascular, Baylis Medical, and Edwards Lifesciences; has institutional educational and consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, and Medtronic; has equity with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Francesco Fulvio Faletra, MD, has received speaker fees from Philips. Ruchira Garg, MD, FASE, has received grant funding from Abbott Medical, was a coinvestigator during the ADOII AS trial, completed Abbott Medical consulting services to provide education related to the Piccolo device, is a coinvestigator in the Alterra Adaptive Prestent trial (Edwards Lifesciences), has received funding from the Pediatric Heart Network (National Heart, Lung, and Blood Institute) for the FUEL (completed) and FUEL-OLE trials (Fontan udenafil medication trial), has participated as a coinvestigator for Daiichi Sankyo in the Ennobleate trial (use of edoxaban oral anticoagulation in pediatric aged patients), and is a consultant for legal case review (ad hoc). Linda D. Gillam, MD, MPH, FASE, is an advisory board member for Edwards Lifesciences and directs core laboratories that have contracts with Edwards Lifesciences and Medtronic (but receives no direct compensation). Kenneth Horton, ACS, RCS, FASE, is a consultant for Edwards Lifesciences, BayLabs, and NeoChord. Omar K. Khalique, MD, FASE, is on the speaker's bureau for Edwards Lifesciences, is a consultant for Cephea Valve, and is director of a CT core lab with trials from multiple device companies (JenaValve, Cephea Valves, Ancora, Lariat) but receives no direct compensation. Stephen H. Little, MD, FASE, has received institutional research support from Abbott, Medtronic, Boston Scientific, 4Tech, and Siemens; and has received personal consulting fees from BayLabs. Gregory M. Scalia, MBBS, FASE, has received fees from Abbott for proctoring regarding the MitraClip. Roberto M. Lang is on the advisory board of Philips Imaging Systems. Dr. Lang has received speaker fees from Philips and Tomtec. Funding Information: The following authors reported relationships with one or more commercial interests: Rebecca T. Hahn, MD, FASE, has received speaker fees from Abbot Vascular, Baylis Medical, and Edwards Lifesciences; has institutional educational and consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, and Medtronic; has equity with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Francesco Fulvio Faletra, MD, has received speaker fees from Philips. Ruchira Garg, MD, FASE, has received grant funding from Abbott Medical , was a coinvestigator during the ADOII AS trial, completed Abbott Medical consulting services to provide education related to the Piccolo device, is a coinvestigator in the Alterra Adaptive Prestent trial (Edwards Lifesciences), has received funding from the Pediatric Heart Network ( National Heart, Lung, and Blood Institute ) for the FUEL (completed) and FUEL-OLE trials (Fontan udenafil medication trial), has participated as a coinvestigator for Daiichi Sankyo in the Ennobleate trial (use of edoxaban oral anticoagulation in pediatric aged patients), and is a consultant for legal case review (ad hoc). Linda D. Gillam, MD, MPH, FASE, is an advisory board member for Edwards Lifesciences and directs core laboratories that have contracts with Edwards Lifesciences and Medtronic (but receives no direct compensation). Kenneth Horton, ACS, RCS, FASE, is a consultant for Edwards Lifesciences, BayLabs, and NeoChord. Omar K. Khalique, MD, FASE, is on the speaker's bureau for Edwards Lifesciences, is a consultant for Cephea Valve, and is director of a CT core lab with trials from multiple device companies (JenaValve, Cephea Valves, Ancora, Lariat) but receives no direct compensation. Stephen H. Little, MD, FASE, has received institutional research support from Abbott , Medtronic , Boston Scientific , 4Tech , and Siemens ; and has received personal consulting fees from BayLabs. Gregory M. Scalia, MBBS, FASE, has received fees from Abbott for proctoring regarding the MitraClip. Roberto M. Lang is on the advisory board of Philips Imaging Systems. Dr. Lang has received speaker fees from Philips and Tomtec.

PY - 2022/1

Y1 - 2022/1

KW - Structural heart disease

KW - Transesophageal echocardiography

UR - http://www.scopus.com/inward/record.url?scp=85115774293&partnerID=8YFLogxK

U2 - 10.1016/j.echo.2021.07.006

DO - 10.1016/j.echo.2021.07.006

M3 - Article

C2 - 34280494

AN - SCOPUS:85115774293

SN - 0894-7317

VL - 35

SP - 1

EP - 76

JO - Journal of the American Society of Echocardiography

JF - Journal of the American Society of Echocardiography

IS - 1

ER -